Cargando…
Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers
BACKGROUND: COX-2 inhibitors can be effective for acute migraine, but none is supplied in a rapidly absorbed, ready-to-use oral liquid formulation. DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura. Clinical studies with...
Autores principales: | Pal, Arindam, Shenoy, Srinivas, Gautam, Anirudh, Munjal, Sagar, Niu, Jing, Gopalakrishnan, Mathangi, Gobburru, Joga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602059/ https://www.ncbi.nlm.nih.gov/pubmed/28748412 http://dx.doi.org/10.1007/s40261-017-0548-6 |
Ejemplares similares
-
Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study
por: Munjal, Sagar, et al.
Publicado: (2017) -
Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Lipton, Richard B., et al.
Publicado: (2019) -
Efficacy and safety of single-dose DFN-15 for treatment of acute postsurgical dental pain: a randomized, double-blind, placebo-controlled study
por: Singla, Neil, et al.
Publicado: (2022) -
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
por: Cady, Roger K., et al.
Publicado: (2017) -
Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)